Listen to discussion on results from a recent Phase 1b clinical trial.
Significant cognitive impairments often accompany schizophrenia. In this Mental Health Minute, Dr Kantrowitz discusses a recent trial of CVN058, a drug that may reduce cognitive impairments in individuals with schizophrenia.
The trial recruited 19 men and women with schizophrenia, giving them a single dose of either CVN058 or a placebo at each study visit. In this video, Dr Kantrowitz reveals the statistically significant results.
Dr Kantrowitz is a psychiatrist at the Nathan Kline Institute and at the New York State Psychiatric Institute. He also serves as assistant professor of Clinical Psychiatry, Columbia University College of Physicians and Surgeons and is Director of the Lieber Research Clinic, New York State Psychiatric Institute.